ILB 2109
Alternative Names: ILB-2109Latest Information Update: 29 May 2024
At a glance
- Originator Innolake Biopharm
- Developer Innolake Biopharm; Shanghai East Hospital
- Class Antineoplastics
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Cancer
Most Recent Events
- 25 Jul 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT05955105)
- 21 Jul 2023 Innolake Biopharm plans a phase I trial for Solid tumours (Combination therapy, Late stage disease, Metastatic) in July 2023 (PO) (NCT05955105)
- 20 Sep 2022 Preclinical trials in Cancer in USA (PO), prior to September 2022 (Innolake Biopharm pipeline, September 2022)